Primary Care Providers Drive Most US Antidepressant Prescriptions, Fueling Overuse Debate

Antidepressant use has expanded markedly since fluoxetine approval in 1987, with SSRIs comprising over half of prescriptions. The MedicalXpress piece notes primary care clinicians write the majority, often after brief PHQ-9 screening that lacks diagnostic specificity for mild versus moderate-to-severe cases. This pattern aligns with observational data showing limited benefit for mild depression where side effects may predominate, while RCTs support efficacy mainly in severe episodes. Collaborative models integrating behavioral health remain uncommon despite evidence they reduce unnecessary starts.

Screening tools flag patients efficiently yet miss nuance in transient symptoms, contributing to prescriptions without full evaluation. Over one-third of suicide decedents visit primary care in the prior month, highlighting detection gaps, but broad application on patients with short-term distress risks overtreatment. Primary providers often lack ready access to psychotherapy or lifestyle interventions, defaulting to medication despite training improvements since earlier decades.

RFK Jr.'s May 2026 initiative targets this by promoting alternatives, yet implementation faces barriers in time-constrained clinics. Patterns mirror earlier expansions of psychiatric drugs where regulatory signals and practice norms outpace granular outcome tracking. Next steps require prospective studies comparing collaborative versus usual primary care on discontinuation rates and long-term functioning.

Evidence quality remains limited by reliance on observational prescribing data without randomization; RCTs focused on primary care workflows and deprescribing thresholds are needed to clarify net benefit.